TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00119392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study: NCT02448238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VSL#3® probiotic
Description: Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (\~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator
Study: NCT05670509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of intramuscular midazolam in ER group as a rescue medication for seizure control.
Description: Children from ER group randomly assigned to receive treatment with intramuscular midazolam with doses of 0.2 mg/kg (maximum, 10 mg) body weight of the standard IV formulation of midazolam (5mg/mL) using 3 mm syringe in the front aspect of thigh
Study: NCT03346590

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Energy metabolism of patients suffering from RA
Description: Energy metabolism of patients suffering from RA
Study: NCT04820088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer based role play trianing
Description: Participants will train with a computer-based role-play simulation. They will interact with a lifelike video character on screen. They will interact with the character in one of four scenarios (i.e., patient intake, traditional needs, high-risk needs,and social and physical transition). They will receive real-time and after-action feedback in a safe, non-stressful environment. Their usage of the system will be monitored and transcripts will be collected.
Study: NCT00841932

Intervention type: PROCEDURE
Intervention: Fractional Flow Reserve
Description: Fractional Flow Reserve performed without anticoagulation
Study: NCT04427124

Intervention type: OTHER
Intervention: Multidisciplinary Team Based Care Model
Description: All prospective patients admitted into the study will receive care based on multidisciplinary team collaboration and an institutional protocol for critical limb ischemia.
Study: NCT03823703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: Tablets taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: Tablets taken orally
Study: NCT03273660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)
Description: First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry.
Study: NCT03679455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 25 MG/ML
Description: Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
Study: NCT03823703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT03072810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive mindfulness program
Description: 4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive mindfulness program
Description: 4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
Study: NCT03137459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM) of health behavior change
Description: Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
Study: NCT02162394

Intervention type: DEVICE
Intervention: Observational ambulatory ECG monitoring
Study: NCT03971539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: BI 894416 film-coated tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet matching BI 894416.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo film-coated tablet matching BI 894416.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet matching BI 894416.
Study: NCT03888807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study: NCT03533452

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local anesthetic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Sham injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Sham injection
Study: NCT03327064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UAB30
Description: 9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
Study: NCT01791842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg/month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg/month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02657707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roadsaver™ Carotid Artery Stent Device
Description: The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanoparasol® Embolic Protection System
Description: The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
Study: NCT01073007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mgrs daily for three months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mgrs daily for three months.
Study: NCT06129721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergent Stenting
Description: Emergent Stenting In Acute Vertebrobasilar Occlusions
Study: NCT05791045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single vs double
Description: we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single vs double
Description: we aimed to compare anesthetic outcomes of single lumen intubation with Heart-Lung Machine mode ventilation versus double lumen intubation study in endoscopic thoracic sympathetic blockade
Study: NCT00905203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training
Study: NCT03002272

Intervention type: DEVICE
Intervention: TAVR
Description: subjects that underwent TAVR more than 3 years ago
Study: NCT01914185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive School Health (CSH)
Description: APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
Study: NCT01962129

Intervention type: BIOLOGICAL
Intervention: Sampling of blood

Intervention type: BIOLOGICAL
Intervention: Sampling of blood
Study: NCT01042730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 1 mg daily or 4 mg daily
Description: Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pitavastatin 1 mg daily or 4 mg daily
Description: Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
Study: NCT01559896

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein hydrolysate capsules and placebo capsules
Description: Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
Study: NCT03002272

Intervention type: DEVICE
Intervention: SAVR
Description: Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
Study: NCT03468322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203
Description: The investigational product is formulated as 1% topical ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle-only control study medication is the same formulation as investigational product without active ingredient
Study: NCT00500760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously (IV; in a vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously (IV; in a vein)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fractionation Radiotherapy
Description: 70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionation Radiotherapy
Description: 70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered intravenously
Study: NCT03403023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tear Film Imager
Description: The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
Study: NCT03133312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Scrub and Paint
Description: Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
Study: NCT00681993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Dense Doxorubucin and Cyclophosphamide
Description: 4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Doxorubucin and Cyclophosphamide
Description: 4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Docetaxel, Carboplatin, and Herceptin
Description: 6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Docetaxel, Doxorubucin and Cyclophosphamide
Description: 3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Docetaxel and Cyclophosphamide
Description: 4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
Study: NCT02058394

Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
Study: NCT05052593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compressive myofascial release
Description: Patients in this group will receive treatment through CMR that includes shaking the muscle belly of vastus lateralis for 30 seconds. Then the hip is fully extended on treatment table and CMR is applied on Vastus lateralis muscle for 1 minute. Treatment consists of broad strokes applied with clinicians knuckles to release superficial restrictions, followed by more specific strokes applied with clinicians' thumb on tight muscle. Strokes are applied at a contact point of 45 degree. With pressure directed from distal to proximal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment group
Description: Patients in this group will receive treatment of Hot pack and Tens for 20 minutes, Range of motion exercises (knee flexion and extension ROM's), Stretching exercises (3sets, 10 reps for 5 second hold)
Study: NCT04001595

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study: NCT03503981

Intervention type: OTHER
Intervention: Psychotherapy
Description: There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.

Intervention type: OTHER
Intervention: Psychotherapy
Description: There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.

Intervention type: OTHER
Intervention: Psychotherapy
Description: There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.

Intervention type: OTHER
Intervention: Psychotherapy
Description: There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.

Intervention type: OTHER
Intervention: Psychotherapy
Description: There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
Study: NCT00619099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m\^2/day. One course will be considered 28 days.
Study: NCT00885482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamiduvine (Epivir)
Description: Epivir 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (Reyataz)
Description: Reyataz 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (Norvir)
Description: Norvir 100 mg
Study: NCT01734330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy in group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine replacement
Study: NCT01434238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling and nutrition supplement
Description: 24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
Study: NCT03365817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioids taper off
Description: Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid stable treatment
Description: No changes on prescribed opioids and adjuvant medication for the next six months
Study: NCT01644617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8237 12 DU
Description: MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily